Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.78 USD | -4.01% | +1.69% | +7.46% |
Jun. 06 | Morgan Stanley Adjusts Price Target on Vir Biotechnology to $15 From $12, Maintains Equal-Weight Rating | MT |
Jun. 05 | Sector Update: Health Care Stocks Steady Premarket Wednesday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.46% | 1.53B | |
+48.46% | 57.87B | |
+41.65% | 40.25B | |
-7.48% | 39.94B | |
-5.96% | 28.54B | |
+12.46% | 26.4B | |
-20.20% | 19.33B | |
+30.06% | 12.4B | |
-0.63% | 12.23B | |
+25.08% | 12.2B |
- Stock Market
- Equities
- VIR Stock
- News Vir Biotechnology, Inc.
- Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule